KT195

Overview

KT195 is a serine hydrolase inhibitor that targets ABHD6 ( IC 50 = 10 nM) and ABHD2 , with no significant activity against DAGLβ. KT195 inhibits endoplasmic reticulum calcium release and mitochondrial calcium uptake by targeting ABHD2, thereby blocking A23187 ( HY-N6687 ) and H 2 O 2 -induced necrotic cell death and apoptosis . By inhibiting ABHD6 activity, KT195 significantly induces 2-AG accumulation in Neuro2A cells and reduces IL-1β secretion in lipopolysaccharide-treated macrophages. KT195 has been used as a negative control probe for DAGLβ and can be applied in studies of ABHD6 and ABHD2 in calcium signaling, lipid metabolism, neuronal function, and inflammatory.

Application

Products | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > CNS Neoplasm | Products > Disease Areas > Lipid Metabolism | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Lipase

Product Information

• Catalog No.: HY-18542
• CAS No.: 1402612-58-1
• Molecular Formula: C27H26N4O2
• Molecular Weight: 438.52
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source